We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Bracco

Offers products, injectors and solutions portfolio for all diagnostic applications from constrast media to medical de... read more Featured Products: More products

Download Mobile App




Groundbreaking AI-Powered Software Significantly Enhances Brain MRI

By MedImaging International staff writers
Posted on 25 Oct 2024
Print article
Image: AiMIFY AI-powered software has received FDA clearance as a Class II SaMD for brain MRI (Photo courtesy of Bracco Diagnostics)
Image: AiMIFY AI-powered software has received FDA clearance as a Class II SaMD for brain MRI (Photo courtesy of Bracco Diagnostics)

Contrast-enhanced magnetic resonance imaging (MRI) utilizes contrast agents to illuminate specific tissues or abnormalities, leading to improved visualization and more comprehensive information. Integrating artificial intelligence (AI) into this process could enhance image interpretation accuracy and efficiency, bolster diagnostic capabilities, and optimize patient care. Now, a groundbreaking AI-powered software has been designed to significantly improve brain MRI, particularly in detecting small and poorly enhanced lesions.

AiMIFY, a collaborative software from Bracco Diagnostics (Milan, Italy) and Subtle Medical (Menlo Park, CA, USA), employs advanced AI technology to increase the contrast enhancement of brain MR images by up to two times the level achieved with a standard dose of gadolinium-based contrast agents (GBCAs). This enhancement allows radiologists and neuroradiologists to obtain clearer, more detailed images, enhancing the visibility of both small and large lesions compared to standard post-contrast images. The software's efficacy has been validated across a wide range of test data, encompassing various patient demographics, pathologies, lesion sizes, MRI scanner vendors, sequences, and acquisition orientations. AiMIFY has received FDA clearance as a Class II software as a medical device (SaMD) specifically for brain MRI.

"This FDA clearance marks a significant milestone for our innovative product, showcasing its potential to transform MRI," said Fulvio Renoldi Bracco, Vice Chairman & Chief Executive Officer of Bracco Imaging S.p.A. "By integrating Bracco's expertise in contrast imaging with Subtle Medical's cutting-edge deep-learning technology, we are poised to redefine diagnostic precision and efficiency, setting new standards in the field for the ultimate benefit of the patients."

"We partnered with Bracco to unlock the potential that AI brings to medical imaging," added Ajit Shankaranarayanan, PhD, Chief Product Officer at Subtle Medical. "The FDA clearance represents a significant milestone for both companies, as we join forces to empower radiological professionals and improve outcomes for patients worldwide with this innovative AI-powered medical imaging solution."

Related Links:
Bracco Diagnostics
Subtle Medical

New
Portable X-ray Unit
AJEX140H
Mobile Barrier
Tilted Mobile Leaded Barrier
Transducer Covers
Surgi Intraoperative Covers
Portable Color Doppler Ultrasound System
S5000

Print article

Channels

Ultrasound

view channel
Image: Experimental design of the study (Photo courtesy of Tatiana Estifeeva et al./Biomaterials Advances)

New Contrast Agent for Ultrasound Imaging Ensures Affordable and Safer Medical Diagnostics

Ultrasound imaging is an affordable and non-invasive diagnostic method that uses widely available equipment. However, its results are often not highly accurate, and the image quality is heavily dependent... Read more

Nuclear Medicine

view channel
Image: PSMA-PET/CT images of an 85-year-old patient with hormone-sensitive prostate cancer (Photo courtesy of Dr. Adrien Holzgreve)

Advanced Imaging Reveals Hidden Metastases in High-Risk Prostate Cancer Patients

Prostate-specific membrane antigen–positron emission tomography (PSMA-PET) imaging has become an essential tool in transforming the way prostate cancer is staged. Using small amounts of radioactive “tracers,”... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.